advances-in-protein-chemistry

More documents

Recommendations

Info

polylactide nanoparticles. Eur J Pharm Biopharm 84: 49-62. 103. SlaninovÃ¡ J, MlsovÃ¡ V, KroupovÃ¡ H, AlÃ¡n L, TÅ¯movÃ¡ T, et al. (2012) Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. Peptides 33: 18-26. 104. Rossi DC, Muñoz JE, Carvalho DD, Belmonte R, Faintuch B, et al. (2012) Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis. BMC Microbiol 12: 28. 105. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J (2003) Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278: 31192-31201. 106. Rousselle C, Clair P, Smirnova M, Kolesnikov Y, Pasternak GW, et al. (2003) Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J Pharmacol Exp Ther 306: 371-376. 107. Adenot M, Merida P, Lahana R (2007) Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Chemotherapy 53: 73-76. 108. Tian XH, Wei F, Wang TX, Wang P, Lin XN, et al. (2012) In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomedicine 7: 1031-1041. 109. Li Y, Zheng X, Cao Z, Xu W, Zhang J, et al. (2012) Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin. Int J Pharm 434: 209-214. 110. Du YZ, Cai LL, Liu P, You J, Yuan H, et al. (2012) Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles. Biomaterials 33: 8858-8867. 111. Wu Y, Sadatmousavi P, Wang R, Lu S, Yuan YF, et al. (2012) Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo. Int J Nanomedicine 7: 3221-3233. 112. Khaksa G, D’Souza R, Lewis S, Udupa N (2000) Pharmacokinetic study of niosome encapsulated insulin. Indian J Exp Biol 38: 901-905. 113. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427. 114. SimÃµes S, Moreira JN, Fonseca C, DÃ¼zgÃ¼neÅŸ N, de Lima MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56: 947-965. 115. Samad A, Sultana Y, Aqil M (2007) Liposomal drug delivery systems: an update review. Curr Drug Deliv 4: 297-305. 116. Irache JM, Salman HH, Gamazo C, Espuelas S (2008) Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 5: 703-724. 117. Grant M, Leone-Bay A (2012) Peptide therapeutics: it’s all in the delivery. Ther Deliv 3: 981-996. 118. Yamada A, Sasada T, Noguchi M, Itoh K (2013) Next-generation peptide vaccines for advanced cancer. Cancer Sci 104: 15-21. 119. Mahato RI, Narang AS, Thoma L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214. 120. Khafagy el-S, Morishita M (2012) Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64: 531-539. 121. He XH, Shaw PC, Tam SC (1999) Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 65: 355-368. 122. Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, et al. (2005) Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 280: 6327-6336. 123. Sun LC, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 8: 2-10. 124. Ahn JM, Boyle NA, MacDonald MT, Janda KD (2002) Peptidomimetics and peptide backbone modifications. Mini Rev Med Chem 2: 463-473. 125. Lozano JM, Espejo F, Ocampo M, Salazar LM, Tovar D, et al. (2004) Mapping the anatomy of a Plasmodium falciparum MSP-1 epitope using pseudopeptide-induced mono- and polyclonal antibodies and CD and NMR conformation analysis. J Struct Biol 148: 110-122. 126. Våbenø J, Lejon T, Nielsen CU, Steffansen B, Chen W, et al. (2004) Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations. J Med Chem 47: 1060-1069. 127. Albericio F, Burger K, Ruíz-Rodríguez J, Spengler J (2005) A new strategy for solid-phase depsipeptide synthesis using recoverable building blocks. Org Lett 7: 597-600. 128. Cruz LJ, Insua MM, Baz JP, Trujillo M, Rodriguez-Mias RA, et al. (2006) IB-01212, a new cytotoxic cyclodepsipeptide isolated from the marine fungus Clonostachys sp. ESNA-A009. J Org Chem 71: 3335-3338. 129. Strömstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M (2009) Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother 53: 593-602. 130. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, et al. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458-464. 131. Wirsching F, Keller M, Hildmann C, Riester D, Schwienhorst A (2003) Directed evolution towards protease-resistant hirudin variants. Mol Genet Metab 80: 451-462. 132. Odegrip R, Coomber D, Eldridge B, Hederer R, Kuhlman PA, et al. (2004) CIS display: In vitro selection of peptides from libraries of protein-DNA complexes. Proc Natl Acad Sci U S A 101: 2806-2810. 133. Eldridge W, Fitzgerald K, Cooley N, McGregor D (2006) Peptide stabilizer compounds and screening methods. Patent Application WO2006097748. 134. Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, et al. (2009) Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 104: 155-163. 135. Ehrlich A, Heyne HU, Winter R, Beyermann M, Haber H, et al. (1996) Cyclization of all-L-Pentapeptides by Means of 1-Hydroxy-7-azabenzotriazole- Derived Uronium and Phosphonium Reagents. J Org Chem 61: 8831-8838. 136. Lioy E, Suarez J, Guzman F, Siegrist S, Pluschke G, et al. (2001) Manuel E. Synthesis, biological, and immunological properties of cyclic peptides from Plasmodium falciparum merozoite surface protein-1. Angewandte Chemie - International Edition in English 40: 2631-2635. 137. Gururaja TL, Narasimhamurthy S, Payan DG, Anderson DC (2000) A novel artificial loop scaffold for the noncovalent constraint of peptides. Chem Biol 7: 515-527. 138. Pakkala M, Hekim C, Soininen P, Leinonen J, Koistinen H, et al. (2007) Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J Pept Sci 13: 348-353. 139. Fernandez-Lopez S, Kim HS, Choi EC, Delgado M, Granja JR, et al. (2001) Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 412: 452-455. 140. Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, et al. (2005) Systemic antibacterial activity of novel synthetic cyclic peptides. OMICS Group eBooks 014
Antimicrob Agents Chemother 49: 3302-3310. 141. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, et al. (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380: 548-550. 142. von Moos E, Ben RN (2005) Recent advances in the synthesis of C-linked glycoconjugates. Curr Top Med Chem 5: 1351-1361. 143. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, et al. (2005) Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 12: 999-1009. 144. Keller G, Schally AV, Nagy A, Baker B, Halmos G, et al. (2006) Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol 28: 1507-1513. 145. Sun LC, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 8: 2-10. 146. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450. 147. Vivès E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017. 148. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97: 13003-13008. 149. Madani F, Lindberg S, Langel U, Futaki S, Gräslund A (2011) Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011: 414729. 150. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, et al. (2005) Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 12: 999-1009. 151. Keller G, Schally AV, Nagy A, Baker B, Halmos G, et al. (2006) Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol 28: 1507-1513. 152. Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp F, et al. (2013) Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. Eur J Pharm Biopharm 83: 338-345. 153. Dombu CY, Betbeder D (2013) Airway delivery of peptides and proteins using nanoparticles. Biomaterials 34: 516-525. 154. Marx V (2005) Watching Peptide Drugs Grow up. C&EN 83: 17-24. OMICS Group eBooks 015
Page 1 and 2:
www.esciencecentral.org/ebooks Adva
Page 3 and 4:
Tyrosine Nitrated Proteins: Biochem
Page 5 and 6:
[58-61]. Protein sulfhydryls [62] a
Page 7 and 8:
2. Souza JM, Daikhin E, Yudkoff M,
Page 9 and 10:
Oligoclonality of the antibody resp
Page 11 and 12:
The Recent Methodologies of Protein
Page 13 and 14:
are due to altering protein activit
Page 15 and 16:
Figure 6: At Domain Level, Protein
Page 17 and 18:
Brownian Dynamics (BD) method Prote
Page 19 and 20:
protein demonstrate the lowest ener
Page 21 and 22:
Figure 12: Steps in Protein Prepara
Page 23 and 24:
FlexServ The flexibility of protein
Page 25 and 26:
21. van der Kamp MW, Shaw KE, Woods
Page 27 and 28:
Advances in Protein Thermodynamics
Page 29 and 30:
3. Fluorescence correlation spectro
Page 31 and 32:
Figure 3: Molecular Chaperone (Top
Page 33 and 34:
Figure 7: A Potherse is Consists of
Page 35 and 36:
Figure 12: Residue Clusters with Mu
Page 37 and 38:
Figure 16: Various Features at the
Page 39 and 40:
Figure 21: Stability of protein str
Page 41 and 42:
Advances in Protein Chemistry Chapt
Page 43 and 44:
MMPs are believed to remodel the EC
Page 45 and 46:
MMPs7 (Matrilysin, PUMP 1) A big ro
Page 47 and 48:
MMP27 (MMP-22, C-MMP) mRNAs for MMP
Page 49 and 50:
Signal transduction MMP production
Page 51 and 52:
a | Active MMPs are generated throu
Page 53 and 54:
Future Perspective Research into ne
Page 55 and 56:
56. Yonemura Y, Endo Y, Fujita H, K
Page 57 and 58:
126. López-Boado YS, Wilson CL, Ho
Page 59 and 60:
Proteins and Peptides- Reemergence
Page 61 and 62:
Figure 3: Schematic representation
Page 63 and 64:
Figure 6: Different mechanisms of c
Page 65 and 66:
[30,33]. Clinical trials with autoi
Page 67 and 68:
Therapeutic Proteins Figure 9: Mole
Page 69 and 70:
Coming years will witness increasin
Page 71 and 72:
Advances in Protein Chemistry Chapt
Page 73 and 74:
purification methodology and laid t
Page 75 and 76:
An overview of various purification
Page 77 and 78:
Affinity chromatography (AC): The p
Page 79 and 80:
molecules such as proteins. Further
Page 81 and 82:
However, for proteins with poor sol
Page 83 and 84:
The schematic of an HPLC instrument
Page 85 and 86: » Denaturation of all proteins giv
Page 87 and 88: Advances in Protein Chemistry Chapt
Page 89 and 90: the biological society access to th
Page 91 and 92: identifier, since a single macromol
Page 93 and 94: Furthermore, the initial models for
Page 95 and 96: evaluation [78], Whatcheck [79] and
Page 97 and 98: corresponding to gaps in the FR ali
Page 99 and 100: programming (IP) problem based on t
Page 101 and 102: or almost the entire target. - Temp
Page 103 and 104: 3.2.1.10 Geno3D http://geno3d-pbil.
Page 105 and 106: 80. Laskowski RA, MacArthur MW, Mos
Page 107 and 108: 165. Zhang Y, Kolinski A, Skolnick
Page 109 and 110: Advances in Protein Chemistry Chapt
Page 111 and 112: Figure 1: Biochemical and biophysic
Page 113 and 114: equilibrium an equilibrium concentr
Page 115 and 116: for virtually all macromolecules to
Page 117 and 118: egion) for estimating fraction or p
Page 119 and 120: etween proteins in living cells. It
Page 121 and 122: pre-requisite in understanding how
Page 123 and 124: 82. Rodger A, Marrington R, Roper D
Page 125 and 126: New Peptide Based Therapeutic Appro
Page 127 and 128: ability to selectively target cells
Page 129 and 130: 24 amino acid extracellular domain
Page 131 and 132: separation efficiency. However, use
Page 133 and 134: the peptides through acetylation an
Page 135: 63. Mesiano AJ, Beckman EJ, Russell
Page 139 and 140: Protein Detection Techniques Dennis
Page 141 and 142: technique has been applied to the i
Page 143 and 144: involves placing our protein of int
show all

advances-in-protein-chemistry

Create successful ePaper yourself

Delete template?

Save as template?